M atrial natriuretic peptide
Alternative Names: Frameshift ANP; Frameshift ANP - Mayo Clinic/E-Star Biotech; Frameshift atrial natriuretic peptide; fsANP; M-atrial natriuretic peptide; MANP; ZD-100Latest Information Update: 26 Nov 2024
Price :
$50 *
At a glance
- Originator Mayo Clinic
- Developer E-Star BioTech; Mayo Clinic
- Class Antihypertensives; Natriuretic peptides
- Mechanism of Action Atrial natriuretic factor receptor A agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Resistant hypertension
- Phase I Essential hypertension
Most Recent Events
- 15 Nov 2024 Phase-II clinical trials in Resistant hypertension (In the elderly, In adults) in USA (SC) (NCT06343298)
- 25 Sep 2024 E-Star BioTech plans the phase II BOLD-HTN trial for Resistant hypertension (SC, Injection), in September 2024 (NCT06343298)
- 28 Oct 2023 No recent reports of development identified for phase-I development in Resistant-hypertension(In the elderly, In adults) in USA (SC, Injection)